SOURCE: Pure Bioscience

PURE Bioscience

November 30, 2015 08:36 ET

PURE Bioscience Hosts Fiscal 2016 Q1 Results Conference Call to Discuss Pending FDA Approvals and Go to Market Plans for PURE Control®

SAN DIEGO, CA--(Marketwired - Nov 30, 2015) - PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that the Company will host an investor conference call on December 10, 2015 at 1:30pm PST (4:30pm EST) to review fiscal 2016 Q1 results.

PURE management will also review:

  • The status of its two FCNs (Food Contact Notifications) with the FDA for the use of SDC
    • Approval for processing raw poultry anticipated in December
    • Approval for processing fresh produce expected early January
  • Targeted calendar Q1 '16 commercialization of PURE Control® as a direct food contact food safety solution for fresh produce processing. Commercialization for raw poultry processing after attaining required USDA approval, and;
  • The progress of ongoing commercialization of PURE® Hard Surface disinfectant in restaurant chains (including SUBWAY Restaurants®*) and processors/manufacturers.

The Participant Dial-In Number for the conference call is 1-631-891-4304. Participants should dial in to the call at least five minutes before 1:30pm PST (4:30pm EST) on December 10, 2015. The call can also be accessed "live" online at http://public.viavid.com/index.php?id=117430

A replay of the recorded call will be available for 90 days on the Company's website (http://www.purebio.com/investors/events-presentations/). You can also listen to a replay of the call by dialing 1-877-870-5176 (international participants dial 1-858-384-5517) starting December 10, 2015, at 7:30pm EST through December 17, 2015 at 11:59 pm EST. Please use PIN Number 117430.

About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at http://www.purebio.com/

* SUBWAY® is a registered trademark of Doctor's Associates Inc.

Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including acceptance of the Company's PURE Hard Surface disinfectant by SUBWAY® franchisees; and the ability to convert successful evaluations into customer orders; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw poultry, produce and raw meat processing; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-Q for the quarterly period ended April 30, 2015 and filed with the SEC on June 15, 2015. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. 

Contact Information

  • Contacts:

    Hank Lambert
    CEO
    PURE Bioscience, Inc.
    619-596-8600 ext.103
    Email Contact

    Terri MacInnis
    VP of IR
    Bibicoff + MacInnis, Inc.
    818-379-8500
    Email Contact

    Tom Hemingway
    Redwood Investment Group
    714-978-4425
    Email Contact